Grant brain tumour patients access to Vorasidenib

Rejected 21 signatures

What the petition asks

Low grade brain tumours have few effective medicines. A recent trial shows Vorasidenib is effective and prolongs life. I ask the UK government to make Vorasidenib available to clinically suitable brain tumour patients in the UK under the Early Access to Medicines Scheme

Trials have taken place in the US and the UK on Low Grade Glioma brain tumour patients. Low Grade Gliomas affect mainly young people. Results of the trials proved very promising. The drug will soon receive FDA approval in the US.

The trials were stopped abruptly in March 2023. There was enough evidence that Vorasidenib significantly reduced the risk of tumour progression or death. The supplier of Vorasidenib has suggested it may make the drug available on a patient-by-patient basis.

Why it was rejected

It asked for something that is not the responsibility of the UK Government or Parliament.

We can only accept petitions about things the Government or Parliament are directly responsible for.

Authorising medication for use in the UK is the responsibility of the Medicines and Healthcare products Regulatory Agency (MHRA), not the UK Government of Parliament. The decision to apply for the Early Access to Medicines Scheme is for pharmaceutical companies and a decision on the outcome of an application is for the MHRA. You can find out more about the process here: https://www.gov.uk/guidance/apply-for-the-early-access-to-medicines-scheme-eams

Timeline

29 Aug 2023	Petition opened for signatures
8 Sep 2023	Rejected by the Petitions Committee

Key facts

Signatures 21

Status Rejected

Rejected 8 Sep 2023

Follow this petition